“Comparative analysis of the use of technetium-99m labeled recombinant target molecules at doses of 1000 and 2000 μg for radionuclide diagnostics of HER2-positive breast cancer” (2022) Voprosy onkologii, 68(1), pp. 60–65. doi:10.37469/0507-3758-2022-68-1-60-65.